Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF Regimens in Chinese Patients With PCV
NCT04380974Phase 4Unknown
- Start
- Jun 2020
- Primary completion
- Oct 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of conbercept in polypoidal choroidal vasculopathy (PCV) (2 arms). Primary endpoint: Polypoidal Choroidal Vasculopathy lesion recurrence at 24 months. Status: unknown.
02
Drugs
conbercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT04380974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380974.